A fourth-generation version of an accommodating IOL (HD-100 crystalens, eyeonics) provides excellent uncorrected visual acuity (UCVA) at all distances without degrading contrast acuity, according to the results of an FDA multicenter clinical trial.
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.